Ajanta Pharmaceuticals Ltd.
NSE: AJANTPHARM · Pharmaceuticals
Snapshot
Unlock Ajanta Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ajanta Pharma Limited is a specialty pharmaceutical company focused on the development, manufacture, and marketing of finished dosage formulations. The company operates across diverse therapeutic segments including cardiology, dermatology, ophthalmology, and pain management, serving both domestic and international markets.
Business Model
The company generates revenue by manufacturing and selling a broad portfolio of pharmaceutical products to private markets and government institutions, including armed forces and public hospitals. Its business model relies on a diversified therapeutic approach and a global distribution network spanning India, Africa, Asia, and the United States.
- Founded:1973
Growth Outlook
Growth is driven by the expansion of its specialty product portfolio and continued penetration into international markets. The company leverages its manufacturing capabilities to supply essential medicines to government bodies and retail healthcare sectors.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or product recalls.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines in India and other markets may compress profit margins.
- Currency Volatility. As a significant exporter, the company is exposed to fluctuations in foreign exchange rates which can impact the profitability of international operations.
- Supply Chain Disruptions. Dependence on global supply chains for active pharmaceutical ingredients (APIs) exposes the company to potential disruptions in raw material availability.
Start your research today
Unlock AI insights, financials, peers and live data on Ajanta Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹6,217 Cr
TTM · consolidated
NET PROFIT
₹1,263 Cr
TTM · consolidated
EPS
₹101.08
TTM · consolidated
RETURN ON EQUITY
27.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
35.4%
TTM · consolidated
P/E
34.7×
Q2 FY27 · consolidated
EV/EBITDA
23.3x
Q2 FY27 · consolidated
EBITDA MARGIN
30.3%
TTM · consolidated
NET PROFIT MARGIN
21.6%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Ajanta Pharmaceuticals Ltd.AJANTPHARM | ₹43,846 Cr | 34.7× | 23.31 | 25.0% | 30.3% | 27.5% | 35.4% | +37.7% |
Gland Pharma Ltd.GLAND | ₹51,086 Cr | 45.2× | 23.16 | 17.6% | 30.8% | 11.6% | 15.7% | +59.0% |
Ipca Laboratories Ltd.IPCALAB | ₹48,909 Cr | 37.3× | 20.50 | 10.6% | 23.7% | 18.3% | 19.4% | +53.4% |
Glaxosmithkline Pharmaceuticals Ltd.GLAXO | ₹42,255 Cr | 40.2× | 27.46 | 5.8% | 37.9% | 50.6% | 61.2% | -3.4% |
J.B. Chemicals & Pharmaceuticals Ltd.JBCHEPHARM | ₹38,730 Cr | 53.2× | — | 5.9% | 28.1% | 18.7% | 23.9% | — |
Emcure Pharmaceuticals Ltd.EMCURE | ₹35,510 Cr | 35.1× | 18.37 | 18.4% | 20.6% | 21.7% | 27.3% | +42.7% |
As of Q2 FY27
Financials
Ajanta Pharmaceuticals Ltd.
NSE: AJANTPHARM · Pharmaceuticals
Snapshot
Unlock Ajanta Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ajanta Pharma Limited is a specialty pharmaceutical company focused on the development, manufacture, and marketing of finished dosage formulations. The company operates across diverse therapeutic segments including cardiology, dermatology, ophthalmology, and pain management, serving both domestic and international markets.
Business Model
The company generates revenue by manufacturing and selling a broad portfolio of pharmaceutical products to private markets and government institutions, including armed forces and public hospitals. Its business model relies on a diversified therapeutic approach and a global distribution network spanning India, Africa, Asia, and the United States.
- Founded:1973
Growth Outlook
Growth is driven by the expansion of its specialty product portfolio and continued penetration into international markets. The company leverages its manufacturing capabilities to supply essential medicines to government bodies and retail healthcare sectors.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or product recalls.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines in India and other markets may compress profit margins.
- Currency Volatility. As a significant exporter, the company is exposed to fluctuations in foreign exchange rates which can impact the profitability of international operations.
- Supply Chain Disruptions. Dependence on global supply chains for active pharmaceutical ingredients (APIs) exposes the company to potential disruptions in raw material availability.
Start your research today
Unlock AI insights, financials, peers and live data on Ajanta Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹6,217 Cr
TTM · consolidated
NET PROFIT
₹1,263 Cr
TTM · consolidated
EPS
₹101.08
TTM · consolidated
RETURN ON EQUITY
27.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
35.4%
TTM · consolidated
P/E
34.7x
Q2 FY27 · consolidated
EV/EBITDA
23.3x
Q2 FY27 · consolidated
EBITDA MARGIN
30.3%
TTM · consolidated
NET PROFIT MARGIN
21.6%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27